Hematology Frontier

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Congress was grandly held in Milan, Italy. This conference brought together top experts and scholars from around the world to discuss cutting-edge topics in basic research and clinical translation in the field of hematolog.Professor Daniel Hartson from the University of Cambridge delivered an insightful presentation on "Deciphering the Genomics of Aggressive Lymphoma." He systematically elaborated on the genetic complexity of Diffuse Large B-cell Lymphoma (DLBCL), shared his team's breakthrough achievements in constructing novel functional genomics models, and emphasized the critical importance of standardized molecular profiling for advancing future clinical research and personalized medicine.

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

The 2025 European Hematology Association (EHA) Annual Congress was grandly convened in Milan, Italy, bringing together the world's top hematology experts for an academic feast. At this congress, Professor Jesús San Miguel of the University of Navarra Clinic in Spain was honored with EHA Lifetime Achievement Award for his revolutionary contributions to the field of Multiple Myeloma (MM). In his award lecture and keynote report, titled "Curing Myeloma: A Long and Winding Road," Professor San Miguel systematically reviewed his 45-year research journey and strategically proposed five core pillars for achieving a cure for MM, charting a clear course for the future of the field.

In 2025, the 30th Annual Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology field, this year's congress attracted thousands of experts and scholars from around the world, with nearly 4,000 abstracts submitted. Among the many studies, a Phase I clinical trial of the novel trispecific antibody JNJ-79635322 (JNJ-5322) (Abstract: S100) was selected by the congress presidency as one of six "outstanding and practice-changing" pivotal studies for an oral presentation during the plenary session, owing to its breakthrough efficacy. The study showcased the astounding potential of JNJ-5322 in treating patients with Relapsed/Refractory Multiple Myeloma (RRMM).

Editor's Note: From June 12 to 15, 2025, the 30th Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology…

At the recently held International Congress of Hematology, treatment advances in the field of Myeloproliferative Neoplasms (MPN) have garnered significant attention. As a classic subtype of MPN, Essential Thrombocythemia (ET) has seen no substantial breakthroughs in its treatment over the past two decades. In a Plenary Presentation, Professor Harry Gill of the University of Hong Kong's School of Clinical Medicine, on behalf of collaborators from 59 research centers worldwide, announced the top-line data from the Phase III SURPASS-ET clinical study. The study confirms that the novel long-acting interferon, Ropeginterferon alfa-2b (hereinafter referred to as Ropeginterferon), is comprehensively superior to the conventional drug anagrelide in both efficacy and safety as a second-line therapy, bringing new hope to patients with high-risk ET.

The 30th European Hematology Association (EHA) Annual Meeting 2025 was grandly held in Milan, Italy, gathering top experts from the global hematology community to discuss and share the latest research progress and cutting-edge technologies in the field. During the Plenary Session, Professor David Curtis from the Australasian Leukaemia and Lymphoma Group (ALLG), on behalf of his team, announced the first results of the ALLG BM12 CAST clinical trial. This Phase III randomized controlled trial, focusing on peripheral blood stem cell transplantation from matched sibling donors, provides powerful "practice-changing" evidence to solve the challenge of Graft-versus-Host Disease (GVHD) prophylaxis, a problem that has puzzled clinicians for nearly forty years, sparking significant interest and heated discussion among attendees.

The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in person, gathering top experts and cutting-edge research from the global hematology community. At this conference, a revolutionary study on the origin of Chronic Lymphocytic Leukemia (CLL) attracted widespread attention. A research team from Spain, using multi-omics single-cell sequencing technologies, revealed that CLL does not, as traditionally believed, originate from a single clone. Instead, in some patients, multiple independent minor clones with the biological characteristics of CLL exist, having emerged and begun to evolve decades before the disease is diagnosed. This discovery not only profoundly reshapes our understanding of CLL pathogenesis but also provides a completely new theoretical basis for future early diagnosis and intervention strategies.

The 2025 European Hematology Association (EHA) Annual Meeting was held in a hybrid format, both online and in-person, gathering top experts and scholars from the global hematology community. The conference focused on the deep integration of cutting-edge technology and clinical practice, with the application of Artificial Intelligence (AI) being one of the core topics. Professor Jakob Nikolas Kather from the Technische Universität Dresden, Germany, was invited to deliver a keynote speech titled "Artificial Intelligence in Hematology: Opportunities, Pitfalls, and How to Bring It into Clinical Practice." He systematically described the revolutionary changes in AI technology from its early explorations to the current era of large models. He particularly highlighted his team's pioneering research on empowering Tumor Board decision-making with AI Agents, charting a course for the future development of AI in hematologic oncology.